GRAL logo

GRAIL LLC (GRAL) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 June 2024

Indexes:

Not included

Description:

GRAIL LLC is a biotechnology company focused on early cancer detection. They develop innovative blood tests that can identify multiple types of cancer at an early stage, improving treatment options and patient outcomes. Their mission is to save lives through advanced diagnostic technology.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

27 Nov '24 Morgan Stanley
Equal-Weight
17 Oct '24 Guggenheim
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GRAL
prnewswire.com18 December 2024

MENLO PARK, Calif. , Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P.

GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAL
marketbeat.com14 December 2024

GRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close.

World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
GRAL
marketwatch.com05 December 2024

Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.

GRAIL to Participate in Upcoming Investor Conferences
GRAIL to Participate in Upcoming Investor Conferences
GRAIL to Participate in Upcoming Investor Conferences
GRAL
prnewswire.com19 November 2024

MENLO PARK, Calif. , Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences.

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
GRAL
prnewswire.com18 November 2024

MENLO PARK, Calif. , Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC.

GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript
GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript
GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript
GRAL
seekingalpha.com15 November 2024

GRAIL Inc. (NASDAQ:GRAL ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Conference Call Participants Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2024 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded.

GRAIL Reports Third Quarter 2024 Financial Results
GRAIL Reports Third Quarter 2024 Financial Results
GRAIL Reports Third Quarter 2024 Financial Results
GRAL
prnewswire.com12 November 2024

Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif. , Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024.

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
GRAL
prnewswire.com04 November 2024

MENLO PARK, Calif. , Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m.

GRAIL to Announce Third Quarter 2024 Financial Results
GRAIL to Announce Third Quarter 2024 Financial Results
GRAIL to Announce Third Quarter 2024 Financial Results
GRAL
prnewswire.com29 October 2024

MENLO PARK, Calif. , Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market on Tuesday, Nov. 12, 2024.

GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference
GRAL
prnewswire.com23 October 2024

Study Participants from Veteran Affairs Sites Include a Diverse Population With Toxic Exposure MENLO PARK, Calif. , Oct. 23, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri® multi-cancer early detection (MCED) test in routine clinical settings.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of GRAIL LLC?
  • What is the ticker symbol for GRAIL LLC?
  • Does GRAIL LLC pay dividends?
  • What sector is GRAIL LLC in?
  • What industry is GRAIL LLC in?
  • What country is GRAIL LLC based in?
  • When did GRAIL LLC go public?
  • Is GRAIL LLC in the S&P 500?
  • Is GRAIL LLC in the NASDAQ 100?
  • Is GRAIL LLC in the Dow Jones?
  • When was GRAIL LLC's last earnings report?
  • When does GRAIL LLC report earnings?
  • Should I buy GRAIL LLC stock now?

What is the primary business of GRAIL LLC?

GRAIL LLC is a biotechnology company focused on early cancer detection. They develop innovative blood tests that can identify multiple types of cancer at an early stage, improving treatment options and patient outcomes. Their mission is to save lives through advanced diagnostic technology.

What is the ticker symbol for GRAIL LLC?

The ticker symbol for GRAIL LLC is NASDAQ:GRAL

Does GRAIL LLC pay dividends?

No, GRAIL LLC does not pay dividends

What sector is GRAIL LLC in?

GRAIL LLC is in the Healthcare sector

What industry is GRAIL LLC in?

GRAIL LLC is in the Diagnostics & Research industry

What country is GRAIL LLC based in?

GRAIL LLC is headquartered in United States

When did GRAIL LLC go public?

GRAIL LLC's initial public offering (IPO) was on 12 June 2024

Is GRAIL LLC in the S&P 500?

No, GRAIL LLC is not included in the S&P 500 index

Is GRAIL LLC in the NASDAQ 100?

No, GRAIL LLC is not included in the NASDAQ 100 index

Is GRAIL LLC in the Dow Jones?

No, GRAIL LLC is not included in the Dow Jones index

When was GRAIL LLC's last earnings report?

GRAIL LLC's most recent earnings report was on 12 November 2024

When does GRAIL LLC report earnings?

The next expected earnings date for GRAIL LLC is 28 February 2025

Should I buy GRAIL LLC stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions